Relmada Therapeutics Statistics
NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.62-0.49 (-15.76%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Relmada Therapeutics by the numbers
Relmada Therapeutics has a market capitalization of $279.5 million based on 106.69M shares outstanding. With trailing EPS of $-0.73, Relmada Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 28.1% below its 50-day average and 51.0% below its 200-day average.
Average daily trading volume is 1.45M shares, or about $3.8 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
RLMD valuation vs. peer median
| Metric | RLMD | Peer median | Difference |
|---|---|---|---|
| Market cap | $279.54M | $282.20M | -1% |
| Avg. volume | 1.45M | 546.98K | +166% |
Peer median across 8 companies: FULC, GLSI, BNTC, GALT, EVMN, VCRE, SPRY, EBS.
Valuation
- Market cap
- $279.54M
- EPS (TTM)
- $-0.73
- Shares outstanding
- 106.69M
Price and trading
- Previous close
- 3.11
- Open
- 3.07
- Day range
- 2.60 – 3.13
- 52-week range
- 2.60 – 8.00
- 52-week change
- -38.64%
- Beta
- —
- Volume
- 2.25M
- Average volume
- 1.45M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 12, 2026
Additional statistics
- Market Cap
- 279.54M
- Forward Pe
- -6.39
- Eps
- -0.73
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 8.00
- Week52 Low
- 2.60
- Avg Volume
- 1.45M
- Shares Outstanding
- 106.69M
- Ma50
- 3.64
- Ma200
- 5.35
- Earnings Date
- Nov 12, 2026
- Pct From52w High
- -67.25%
- Pct From52w Low
- 0.67%